Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason T Huse

Showing results (151-160 of 188) with videos related to

Pageof 19
Sort By:
Neuro-Oncology|August 29, 2014
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working GroupBrian M Alexander, Evanthia Galanis, W K Alfred Yung, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and ResistanceMostafa I H Ali, Zeynep Feyza Akpinar, Jose A Ovando-Ricardez, et al.
Scientific Reports|June 11, 2016
IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulationYavuz Oktay, Ege Ülgen, Özge Can, et al.
JCI Insight|March 22, 2022
Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expressionHinda Najem, Martina Ott, Cynthia Kassab, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
Interplay between <i>ATRX</i> and <i>IDH1</i> mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Neuro-Oncology|June 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Martin J van den Bent, Pim J French, Daniel Brat, et al.
Nature Communications|January 25, 2024
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma PatientsEudocia Q Lee, Thomas J Kaley, Dan G Duda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastomaAntonio Omuro, Kathryn Beal, Philip Gutin, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2026
Multi-Omics Study of Ancestry in Adults with Intracranial Cancers - Glioma (MOSAIC)Melissa L Bondy, Humaira Noor, Spiridon Tsavachidis, et al.
Pageof 19

Showing results (151-160 of 188) with videos related to

Sort By:
Pageof 19
Neuro-Oncology|August 29, 2014
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working GroupBrian M Alexander, Evanthia Galanis, W K Alfred Yung, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and ResistanceMostafa I H Ali, Zeynep Feyza Akpinar, Jose A Ovando-Ricardez, et al.
Scientific Reports|June 11, 2016
IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulationYavuz Oktay, Ege Ülgen, Özge Can, et al.
JCI Insight|March 22, 2022
Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expressionHinda Najem, Martina Ott, Cynthia Kassab, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
Interplay between <i>ATRX</i> and <i>IDH1</i> mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Neuro-Oncology|June 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Martin J van den Bent, Pim J French, Daniel Brat, et al.
Nature Communications|January 25, 2024
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomasSeethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma PatientsEudocia Q Lee, Thomas J Kaley, Dan G Duda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastomaAntonio Omuro, Kathryn Beal, Philip Gutin, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2026
Multi-Omics Study of Ancestry in Adults with Intracranial Cancers - Glioma (MOSAIC)Melissa L Bondy, Humaira Noor, Spiridon Tsavachidis, et al.
Pageof 19